Details about Johann Matthias Graf von der Schulenburg

Access statistics for papers by Johann Matthias Graf von der Schulenburg.

Last updated 2024-05-07. Update your information in the RePEc Author Service.

Short-id: pgr520

Working Papers

2015

1. Cost of poor adherence to anti-hypertensive therapy in five European countries
   Post-Print, HAL View citations (3)

2014

2. Grundlagen und Methoden von GKV-Routinedatenstudien
   Hannover Economic Papers (HEP), Leibniz Universität Hannover, Wirtschaftswissenschaftliche Fakultät View citations (3)

2013

3. Cost of Poor Adherence to Anti-Hypertensive Therapy in Europe
   CEIS Research Paper, Tor Vergata University, CEIS

Journal Articles

2023

1. Digital Transformation in Back-Offices of German Insurance Companies
   International Journal of Innovation and Technology Management (IJITM), 2023, 20, (08), 1-27

2022

2. Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments
   Health Policy, 2022, 126, (1), 49-59 View citations (1)

2021

3. COVID-19: not the time for health economists? A plea for more proactive health economic involvement
   The European Journal of Health Economics, 2021, 22, (7), 1001-1004

2020

4. Affirmative and silent cyber coverage in traditional insurance policies: Qualitative content analysis of selected insurance products from the German insurance market
   The Geneva Papers on Risk and Insurance - Issues and Practice, 2020, 45, (4), 657-689 View citations (1)
5. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
   The European Journal of Health Economics, 2020, 21, (9), 1421-1437 View citations (2)

2019

6. Correction to: An Urban Crisis Management System for Critical Infrastructures: Participation Possibilities for Insurance Companies
   The Geneva Papers on Risk and Insurance - Issues and Practice, 2019, 44, (2), 357-358

2018

7. German Value Set for the EQ-5D-5L
   PharmacoEconomics, 2018, 36, (6), 663-674 View citations (19)
8. “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
   Health Economics Review, 2018, 8, (1), 1-11 View citations (1)

2017

9. An Urban Crisis Management System for Critical Infrastructures: Participation Possibilities for Insurance Companies
   The Geneva Papers on Risk and Insurance - Issues and Practice, 2017, 42, (4), 633-656

2016

10. Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany
    Applied Health Economics and Health Policy, 2016, 14, (4), 441-452
11. Benefit assessment in Germany: implications for price discounts
    Health Economics Review, 2016, 6, (1), 1-12 View citations (3)
12. Measuring patients’ priorities using the Analytic Hierarchy Process in comparison with Best-Worst-Scaling and rating cards: methodological aspects and ranking tasks
    Health Economics Review, 2016, 6, (1), 1-11 View citations (3)
13. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe
    The European Journal of Health Economics, 2016, 17, (1), 79-87 View citations (15)

2015

14. Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis -
    Health Economics Review, 2015, 5, (1), 1-9 View citations (1)
15. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems
    The European Journal of Health Economics, 2015, 16, (2), 113-118 View citations (3)
16. Regional differences in health care of patients with inflammatory bowel disease in Germany
    Health Economics Review, 2015, 5, (1), 1-11

2014

17. Entwicklung der Leistungsempfängerzahlen in der Gesetzlichen Pflegeversicherung - Zum Einfluss unterschiedlicher Morbiditätsannahmen auf die Entwicklung der sozialrechtlich anerkannten Pflegebedürftigkeit in Deutschland
    Schmollers Jahrbuch : Journal of Applied Social Science Studies / Zeitschrift für Wirtschafts- und Sozialwissenschaften, 2014, 134, (2), 209-236

2013

18. Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system
    Health Economics Review, 2013, 3, (1), 1-17

2012

19. Corporate Management of Highly Dynamic Risks: Evidence from the Demand for Terrorism Insurance in Germany
    The Geneva Risk and Insurance Review, 2012, 37, (1), 57-82 View citations (3)
20. Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study
    Health Policy, 2012, 108, (1), 19-26 View citations (6)
21. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
    Health Economics Review, 2012, 2, (1), 1-13 View citations (4)

2011

22. Greetings from the Editors
    Health Economics Review, 2011, 1, (1), 1-2
23. Letter from the editors
    The European Journal of Health Economics, 2011, 12, (1), 1-1
24. Measuring economic consequences of preterm birth - Methodological recommendations for the evaluation of personal burden on children and their caregivers
    Health Economics Review, 2011, 1, (1), 1-10 View citations (3)
25. Promoting vaccinations - an analysis of measures taken by German statutory health insurers
    Health Economics Review, 2011, 1, (1), 1-6

2010

26. Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer
    The European Journal of Health Economics, 2010, 10, (1), 21-26 View citations (1)
27. EJHE has an official impact factor of 1.337
    The European Journal of Health Economics, 2010, 11, (5), 435-435
28. Impact of the Introduction of the Social Long-Term Care Insurance in Germany on Financial Security Assessment in Case of Long-Term Care Need&ast
    The Geneva Papers on Risk and Insurance - Issues and Practice, 2010, 35, (4), 626-643 View citations (8)
29. On the Impact of the Financial Crisis on the Dividend Policy of the European Insurance Industry
    The Geneva Papers on Risk and Insurance - Issues and Practice, 2010, 35, (1), 53-62 View citations (4)

2009

30. Reinsurance Brokers and Advice Quality: Is There a Need for Regulation&quest
    The Geneva Risk and Insurance Review, 2009, 34, (1), 20-46 View citations (2)

2007

31. Editor’s note
    The European Journal of Health Economics, 2007, 8, (3), 179-179
32. Nach welchen ökonomischen Methoden sollten Gesundheitsleistungen in Deutschland evaluiert werden? / According to Which Economic Methods Should Health Care Services Become Evaluated in Germany?
    Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), 2007, 227, (5-6), 787-806

2005

33. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
    The European Journal of Health Economics, 2005, 6, (4), 317-321 View citations (1)
34. German health care system in transition
    The European Journal of Health Economics, 2005, 6, (2), 183-187 View citations (4)
35. Validating the EQ-5D with time trade off for the German population
    The European Journal of Health Economics, 2005, 6, (2), 124-130 View citations (20)

2002

36. Commentary
    The European Journal of Health Economics, 2002, 3, (2), 138-138 View citations (3)
37. Diffusion of innovations: treatment of Alzheimer's disease in Germany
    Health Policy, 2002, 60, (1), 59-66 View citations (1)

1993

38. Bonus options in health insurance by Peter Zweifel. Awer Academic Publishers, Dordrecht, 1992. No. of ges: xii + 141. ISBN 0‐7923‐1722‐X
    Health Economics, 1993, 2, (1), 81-82

1991

39. Reliability of Risk Management: Market Insurance, Self-Insurance and Self-Protection Reconsidered
    The Geneva Risk and Insurance Review, 1991, 16, (1), 45-58 View citations (19)

1987

40. Voting on Social Security: The Family as Decision‐Making Unit
    Kyklos, 1987, 40, (4), 529-547 View citations (6)

Edited books

2014

1. Operations Research Proceedings 2012
   Operations Research Proceedings, Springer View citations (9)

Editor

1. Health Economics Review
   Springer